The estimated economic burden of genital herpes in the United States. An analysis using two costing approaches

BMC Infectious Diseases

Table 2 Estimated costs of genital herpes in the USA (physicians' study)

	Costs (in	% of direct costs	% of total costs
	thousands US$)
Consultations/lab testing (n)
First episodes (422,950)	74,016
1 to 2 (104,150)	19,684
3 to 6 (468,650)	265,725
7 or more (124,970)	110,224
Subtotal	469,649	47.7%
Drugs (n)
First episodes (422,950)	27,069
1 to 2 (104,150)	20,465
3 to 6 (468,650)	303,685
7 or more (124,970)	137,342
Subtotal	488,561	49.7%
Hospital (n)
First episodes (422,950)	424
1 to 2 (104,150)	1,250
3 to 6 (468,650)	16,871
7 or more (124,970)	6,998
Subtotal	25,543	2.6%
Total direct costs (n)
First episodes (422,950)	101,508
1 to 2 (104,150)	41,400
3 to 6 (468,650)	586,281
7 or more (124,970)	254,654
Total	*983,843*	100%	*82.1%*
Total indirect costs (n)
First episodes (422,950)	25,377
1 to 2 (104,150)	9,373
3 to 6 (468,650)	126,536
7 or more (124,970)	52,487
Total	213,773		*17.9%*
Total direct plus indirect costs
First episodes (422,950)	126,885
1 to 2 (104,150)	50,773
3 to 6 (468,650)	712,817
7 or more (124,970)	307,051
	*1,197,526*		*100%*

ISSN: 1471-2334